

PE/iFluor™ 700 Anti-human CD27 Antibody
O323Catalog number: 102711U0, 102711U1, 102711U2
Unit size: 25 tests, 100 tests, 500 tests**Product Details**

Storage Conditions	2-8°C with minimized light exposure. Do not freeze.
Expiration Date	12 months upon receiving
Concentration	0.1 mg/mL
Formulation	Phosphate-buffered saline (PBS, pH 7.2), 0.09% sodium azide, 0.2% (w/v) BSA

Antibody Properties

Species Reactivity	Human
Class	Primary
Clonality	Monoclonal
Host	Mouse
Isotype	Mouse IgG1, κ
Immunogen	CD27 (T14, S152, TNFRSF7)
Clone	O323
Conjugate	PE/iFluor™ 700

Biological Properties

Preparation	Antibody purified by affinity chromatography and then conjugated with PE/iFluor™ 700 under optimal conditions
Application	Flow Cytometry (FACS)

Spectral Properties

Conjugate	PE/iFluor™ 700
Excitation Wavelength	566 nm
Emission Wavelength	708 nm

Applications

O323 is an anti-human monoclonal antibody that is specific for the CD27 antigen. CD27 (also known as S152, TNFRSF7 or T14) is a 50 - 55 kD single-pass type I membrane protein that is found on the surface of cells such as T cells, B cells and NK cells. In some organisms, CD27 promotes B cell differentiation, inhibits apoptotic process and positively regulates NIK/NF-kappaB signaling. Additionally, it is a member of vital cellular pathways, for instance, the extrinsic apoptotic signaling pathway, cell surface receptor signaling pathway and tumor necrosis factor-mediated signaling pathway. From a research standpoint, it is of biological interest due to its association with key macromolecules/ligands such as CD70.

CD27 is a moderately popular antibody target, with over 11000 publications in the last decade. CD27 is vital to costimulatory molecules research, typically serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to PE/iFluor™ 700 (ex/em = 566/708 nm). It is compatible with the 561 nm laser and 695/40 nm bandpass filter (for example, as in the Agilent Technologies NovoCyte Advanteon).